Q2 Earnings Forecast for Alumis Issued By Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for Alumis in a report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($1.48) per share for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. Leerink Partnrs also issued estimates for Alumis’ Q3 2025 earnings at ($1.38) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.46) EPS, FY2026 earnings at ($5.19) EPS, FY2027 earnings at ($6.13) EPS, FY2028 earnings at ($3.99) EPS and FY2029 earnings at ($2.04) EPS.

ALMS has been the topic of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $15.00 price target (down from $19.00) on shares of Alumis in a research note on Thursday, March 20th. Finally, Oppenheimer began coverage on shares of Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Alumis currently has a consensus rating of “Buy” and a consensus price target of $26.00.

Alumis Stock Performance

NASDAQ ALMS opened at $4.00 on Wednesday. The stock’s 50-day simple moving average is $5.55 and its two-hundred day simple moving average is $8.43. Alumis has a twelve month low of $3.18 and a twelve month high of $13.53.

Institutional Investors Weigh In On Alumis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Foresite Capital Management VI LLC purchased a new position in shares of Alumis in the fourth quarter valued at about $33,033,000. Samsara BioCapital LLC bought a new stake in shares of Alumis in the third quarter worth about $34,886,000. Geode Capital Management LLC purchased a new position in Alumis during the 3rd quarter valued at about $3,266,000. Norges Bank bought a new position in Alumis during the 4th quarter valued at approximately $1,606,000. Finally, Foresite Capital Management V LLC lifted its holdings in Alumis by 3.5% in the 4th quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after buying an additional 194,459 shares during the period.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.